Related Experiment Video
Updated: May 28, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Nitroglycerin use in myocardial infarction patients
Julio C B Ferreira1, Daria Mochly-Rosen
1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305-5174, USA.
Summary
Nitroglycerin (glyceryl trinitrate) is a key treatment for heart attacks, but tolerance develops. Alda-1, an ALDH2 activator, prevents negative effects of nitroglycerin, improving outcomes in myocardial infarction models.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Acute myocardial infarction (MI) is a major global health concern.
- Nitroglycerin (glyceryl trinitrate, GTN) is a primary treatment for angina and MI, acting via nitric oxide (NO) for vasodilation.
- Continuous GTN use leads to tolerance, partly due to aldehyde dehydrogenase 2 (ALDH2) inactivation.
Purpose of the Study:
- To review the molecular mechanisms of nitroglycerin (GTN) benefits and risks in myocardial infarction (MI).
- To explore how GTN tolerance impacts cardiomyocyte viability and infarct size.
- To investigate the potential of Alda-1, an ALDH2 activator, in mitigating GTN's adverse effects.
Main Methods:
- Review of existing literature on nitroglycerin (GTN) and aldehyde dehydrogenase 2 (ALDH2) in myocardial infarction (MI) models.
- Analysis of molecular pathways involved in GTN metabolism and tolerance.
- Examination of studies using Alda-1 in conjunction with GTN in animal MI models.
Main Results:
- Sustained GTN treatment in MI models can impair cardiomyocyte viability and increase infarct size.
- Nitroglycerin tolerance is linked to aldehyde dehydrogenase 2 (ALDH2) inactivation.
- Coadministration of Alda-1 with GTN improved cardiac function and reduced infarct size in animal models.
Conclusions:
- Alda-1 can prevent the detrimental effects of GTN on cardiac function post-MI by enhancing ALDH2 activity.
- Understanding the molecular mechanisms of GTN tolerance is crucial for optimizing its clinical use.
- Targeting ALDH2 offers a potential strategy to improve the efficacy and safety of GTN in acute myocardial infarction management.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...